Thomas Van Cann

700 total citations
11 papers, 368 citations indexed

About

Thomas Van Cann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Thomas Van Cann has authored 11 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Thomas Van Cann's work include Sarcoma Diagnosis and Treatment (6 papers), Vascular Tumors and Angiosarcomas (5 papers) and Bone health and treatments (3 papers). Thomas Van Cann is often cited by papers focused on Sarcoma Diagnosis and Treatment (6 papers), Vascular Tumors and Angiosarcomas (5 papers) and Bone health and treatments (3 papers). Thomas Van Cann collaborates with scholars based in Belgium, Netherlands and United Kingdom. Thomas Van Cann's co-authors include Patrick Schöffski, Agnieszka Woźniak, Raf Sciot, Maria Dêbiec‐Rychter, Jasmien Cornillie, Benoit Beuselinck, Herlinde Dumez, Ludo Willems, Philip R. Debruyne and Jozef Šufliarský and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Thomas Van Cann

11 papers receiving 365 citations

Peers

Thomas Van Cann

ONCOL

PRM

RHEUM

OSM

EPIDE

Laura Yébenes Spain

Francesco Pietrogrande Italy

Wanlim Kim South Korea

M Avella Italy

Sharjeel Usmani Kuwait

Fahad Marafi Kuwait

Jill L. Caudill United States

Michael Borofsky United States

Cheuk Hong Leung United States

Anthony P. Martinez United States

Laura Yébenes Spain

Thomas Van Cann

134 ×0.6

ONCOL

93 ×0.6

PRM

48 ×0.5

RHEUM

55 ×0.6

OSM

29 ×0.5

EPIDE

Citations per year, relative to Thomas Van Cann Thomas Van Cann (= 1×) peers Laura Yébenes

Countries citing papers authored by Thomas Van Cann

Since Specialization

Citations

This map shows the geographic impact of Thomas Van Cann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Van Cann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Van Cann more than expected).

Fields of papers citing papers by Thomas Van Cann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Van Cann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Van Cann. The network helps show where Thomas Van Cann may publish in the future.

Co-authorship network of co-authors of Thomas Van Cann

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Van Cann. A scholar is included among the top collaborators of Thomas Van Cann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Van Cann. Thomas Van Cann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Woźniak, Agnieszka, Thomas Van Cann, Jasmien Wellens, et al.. (2021). Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. Sarcoma. 2021. 1–12. 6 indexed citations

Cornillie, Jasmien, Thomas Van Cann, Agnieszka Woźniak, et al.. (2019). Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center. Oncology Research and Treatment. 42(7-8). 396–404. 15 indexed citations

Schöffski, Patrick, Jozef Šufliarský, Hans Gelderblom, et al.. (2018). Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. The Lancet Respiratory Medicine. 6(6). 431–441. 123 indexed citations

Schöffski, Patrick, Jozef Šufliarský, Hans Gelderblom, et al.. (2018). Abstract CT045: Prospective precision medicine trial of crizotinib (C) in patients (pts) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alterations: EORTC phase II study 90101 "CREATE". Cancer Research. 78(13_Supplement). CT045–CT045. 2 indexed citations

Cann, Thomas Van, Patrick Schöffski, Paul Clement, et al.. (2017). Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clinica Belgica. 73(2). 100–109. 40 indexed citations

Cann, Thomas Van, Annelies Verbiest, Paul Clement, et al.. (2017). Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Supportive Care in Cancer. 26(3). 869–878. 42 indexed citations

Sciot, Raf, Marion Delcroix, Maria Dêbiec‐Rychter, et al.. (2017). Single-Center Experience with Intimal Sarcoma, an Ultra-Orphan, Commonly Fatal Mesenchymal Malignancy. Oncology Research and Treatment. 40(6). 353–359. 20 indexed citations

Schöffski, Patrick, Thomas Van Cann, & Jasmien Cornillie. (2017). Treatment options for anthracycline-resistant, advanced soft-tissue sarcoma: the role of eribulin. Expert Opinion on Orphan Drugs. 5(5). 445–453. 2 indexed citations

Sciot, Raf, Marion Delcroix, Maria Dêbiec‐Rychter, et al.. (2017). Single-center experience with intimal sarcoma, an ultra-orphan, commonly fatal mesenchymal malignancy.. Journal of Clinical Oncology. 35(15_suppl). e22532–e22532. 4 indexed citations

10.

Cornillie, Jasmien, Thomas Van Cann, Agnieszka Woźniak, Daphne Hompes, & Patrick Schöffski. (2016). Biology and management of clear cell sarcoma: state of the art and future perspectives. Expert Review of Anticancer Therapy. 16(8). 839–845. 28 indexed citations

11.

Beuselinck, Benoit, Pascal Wolter, Alexandra Karadimou, et al.. (2012). Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. British Journal of Cancer. 107(10). 1665–1671. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact